EPISODE · Aug 23, 2026 · 8 MIN
今天3分钟我们来聊聊肺癌耐药新突破！中国双抗ADC来了
from 源于细胞BioInsid的个人播客
肺癌靶向药耐药别慌！中国原创双抗ADC伦康依隆妥单抗，像双头导弹同时锁定EGFR和HER3，堵死肿瘤耐药通路。四项III期临床全成功，BMS花84亿美元买海外权益，为耐药患者带来新希望，但85%的≥3级不良反应需警惕。参考文献：百利天恒公告. 伦康依隆妥单抗用于非小细胞肺癌III期临床达到主要终点. 2026-08-18医药魔方. 百利天恒EGFR/HER3双抗ADC又一项III期研究成功. 2026-08-17药时空. 全球首个！百利天恒双抗ADC又一项III期研究成功. 2026-08-18肿瘤时间/丁香园. 孟祥姣教授深度解读伦康依隆妥单抗生存数据与全程安全管理. 2026-08-12新浪财经. NSCLC双抗ADC治疗迎来III期首捷. 2026-08-18前往小宇宙评论区与主播互动
Embed this episode
Ready to play
今天3分钟我们来聊聊肺癌耐药新突破！中国双抗ADC来了
0:00
8:26
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
Frequently Asked Questions
How long is this episode of 源于细胞BioInsid的个人播客?
This episode is 8 minutes long.
When was this 源于细胞BioInsid的个人播客 episode published?
This episode was published on August 23, 2026.
Can I download this 源于细胞BioInsid的个人播客 episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!